Back to search
Wet Age-related Macular Degeneration (wAMD)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Wet Age-related Macular Degeneration (wAMD) trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Wet Age-related Macular Degeneration (wAMD) trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-…
The purpose of this study is to evaluate safety, effectiveness and durability of a gene therapy called Ixo-vec (Ixoberogene soroparvovec) when administered to t…
ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (…
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will eval…
This is a phase III, multicenter, randomized double-blinded clinical trial with two parallel groups (ranibizumab and bevacizumab) and an observational follow-up…
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.